Centessa Pharmaceuticals plc
NASDAQ:CNTA
15.81 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 6.913 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.236 | 0.24 | 0.248 | 0.237 | 0.238 | 0.09 | 0.036 | 0.035 | 0.032 | 0.028 | 0.012 | 0.013 | 0 | 0.002 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.236 | -0.24 | 6.664 | -0.237 | -0.238 | -0.09 | -0.036 | -0.035 | -0.032 | -0.028 | -0.012 | -0.013 | 0 | -0.002 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.964 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 32.852 | 22.639 | 29.975 | 28.19 | 33.673 | 32.826 | 27.835 | 36.744 | 53.651 | 36.853 | 41.534 | 25.85 | 18.134 | 10.779 | 0.994 | 2.574 | 1.871 | 3.333 |
| General & Administrative Expenses
| 11.165 | 13.438 | 12.315 | 12.019 | 13.346 | 16.051 | 13.768 | 12.284 | 14.763 | 14.385 | 12.988 | 12.464 | 11.841 | 5.716 | 0.308 | 0.193 | 0.258 | 0.383 |
| Selling & Marketing Expenses
| 0.013 | -0.248 | -0.141 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.523 | 0 | 0 | 0 | 0 |
| SG&A
| 10.941 | 13.19 | 12.174 | 12.019 | 13.346 | 16.051 | 13.768 | 12.284 | 14.763 | 14.385 | 12.988 | 12.464 | 11.841 | 8.239 | 0.308 | 0.193 | 0.258 | 0.383 |
| Other Expenses
| 0.154 | -1.537 | -0.878 | -1.677 | -1.527 | -1.346 | -0.07 | -3.143 | 5.359 | 0.196 | 0.235 | -1.906 | -0.191 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 43.793 | 35.83 | 42.148 | 40.209 | 47.019 | 48.877 | 41.603 | 49.028 | 68.414 | 51.238 | 54.522 | 38.314 | 29.975 | 19.019 | 3.184 | 2.038 | 2.139 | 2.925 |
| Operating Income
| -44.029 | -36.069 | -35.484 | -40.209 | -47.019 | -48.877 | -41.603 | -49.028 | -68.414 | -53.218 | -58.292 | -38.314 | -41.287 | -19.021 | -3.005 | -2.116 | -2.129 | -3.192 |
| Operating Income Ratio
| 0 | 0 | -5.133 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.87 | -1.474 | -0.519 | -1.677 | -1.527 | -1.16 | -2.234 | -4.988 | 3.731 | -1.2 | -3.535 | -1.906 | -11.503 | -221.267 | -0.281 | -0.022 | -0.099 | 0.181 |
| Income Before Tax
| -43.159 | -37.544 | -36.003 | -41.474 | -48.937 | -50.037 | -43.837 | -54.016 | -64.683 | -54.418 | -60.66 | -40.155 | -41.451 | -240.288 | -3.286 | -2.138 | -2.228 | -3.011 |
| Income Before Tax Ratio
| 0 | 0 | -5.208 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.706 | 0.481 | 1.154 | -2.826 | -24.051 | 0.677 | -0.664 | -0.141 | -0.022 | 0.08 | 0.114 | -0.065 | -11.339 | 0 | 0 | -0.022 | -0.099 | 0.181 |
| Net Income
| -43.865 | -38.024 | -37.157 | -38.648 | -24.886 | -50.714 | -43.173 | -53.875 | -64.661 | -54.498 | -60.774 | -40.155 | -41.451 | -240.288 | -3.286 | -2.138 | -2.228 | -3.011 |
| Net Income Ratio
| 0 | 0 | -5.375 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.4 | -0.38 | -0.38 | -0.4 | -0.26 | -0.53 | -0.46 | -0.57 | -0.69 | -0.6 | -0.68 | -0.45 | -0.65 | -2.75 | -0.22 | -0.015 | 0 | 0 |
| EPS Diluted
| -0.4 | -0.38 | -0.38 | -0.4 | -0.26 | -0.53 | -0.46 | -0.57 | -0.69 | -0.6 | -0.68 | -0.45 | -0.65 | -2.75 | -0.22 | -0.015 | 0 | 0 |
| EBITDA
| -43.793 | -35.83 | -35.236 | -38.695 | -46.25 | -47.603 | -41.673 | -52.136 | -63.023 | -51.014 | -55.618 | -40.155 | -30.139 | -19.019 | -3.004 | -0.022 | -0.099 | 0.181 |
| EBITDA Ratio
| 0 | 0 | -5.097 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |